Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on CytoMed Therapeutics (NASDAQ:GDTC) and maintained a $5 price target for the company's stock.
December 04, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reaffirmed a Speculative Buy rating on CytoMed Therapeutics and kept the price target at $5.
The reiteration of a Speculative Buy rating and the maintenance of a $5 price target by a Benchmark analyst could lead to increased investor confidence in CytoMed Therapeutics. This endorsement may positively influence the stock's short-term performance as it suggests the analyst sees potential upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100